Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prednisone plus azathioprine vs prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Nicotinamide plus tetracycline vs prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Clobetasol propionate cream vs oral prednisone Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Mild clobetasol propionate cream regimen (10 to 30 g/day) vs standard clobetasol propionate cream regimen (40 g/day) Quality of life ‐ not measured · bullous pemphigoid Interventions for bullous pemphigoid (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Quality of Life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Time to recurrence ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab) Quality of life ‐ not measured · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Overall survival (OS) · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Time to response ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Overall response rate (ORR), · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab) Quality of life ‐ not measured · stage III cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Overall survival (OS) · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Adverse events · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Time to recurrence — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy Quality of life — not reported · stage III and IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Neoadjuvant treatment vs no neoadjuvant treatment Quality of life ‐ not measured · stage III or IV cutaneous melanoma Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs no IVIG Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |